Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Abbott Laboratories enters its October 21 Q3 results having already delivered one strong print this season, with the stock up 5.3% on the week and options positioning flashing the most defensive signal it has shown in months.
The clearest pre-earnings signal is in the derivatives market. Options traders have turned more cautious than at any point in recent memory, with the put/call ratio climbing to 0.66, more than two standard deviations above its 20-day average of 0.62. That is the highest defensive skew since at least mid-summer, despite the stock rallying to $104.89. The backdrop from the lending market is the polar opposite: short interest has collapsed by 28% over the past month to just 0.84% of the free float, borrow costs are minimal at 0.38%, and availability remains essentially unconstrained. Short sellers are not pressing the case against Abbott. The hedging in options markets therefore looks less like a directional bear bet and more like event-protection from holders unwilling to give back a week's worth of gains into the release.
The analyst community has grown more constructive since the previous preview. TD Cowen reiterated its Buy at $135 on October 16, the day before the print window. Barclays, which only initiated coverage at Overweight with a $120 target earlier this month, and Rothschild, which upgraded to Buy and raised its target to $127 at the start of October, have added fresh bullish voices to a consensus that already sits firmly in Buy territory with a mean target of $120.72. That implies roughly 15% upside to the current price, a gap that has narrowed from the 20%-plus discount flagged in the previous article but remains meaningful. Bulls point to the July quarter beat, where revenue of $12.59 billion and EPS of $1.31 exceeded expectations, gross margin expanded to 58%, and management raised full-year adjusted EPS guidance to $5.45 to $5.60. The TactiFlex Duo FDA approval and strong FlexPulse data give the cardiovascular franchise a concrete near-term catalyst. Bears counter with pricing pressure in global nutrition, procedure volume risk in medical devices, and a roughly 60% international revenue mix that leaves Abbott exposed to foreign exchange headwinds and macro softness.
The stock's own earnings history adds texture. The July print delivered a one-day gain of 12.8% and a five-day move of 12.9%, an unusually large reaction for a company of Abbott's size. The October 14 event, which appears to be a subsequent reporting date in the data, produced a 2% one-day move. Peer performance has been broadly supportive: MDT rose 7.1% on the week, SYK gained 6.2%, and COO added 6.6%, suggesting sector tailwinds rather than Abbott-specific enthusiasm behind the recent recovery. BlackRock added 6.9 million shares in the quarter to September, bringing its holding to 8.8% of shares outstanding, while T. Rowe Price added 3 million shares over the same period, the two largest absolute additions among top holders.
The October 21 print will test whether the guidance raise from July carries through to Q3 numbers, and whether the Street's consensus targets, now 15% above the stock, are grounded in organic progress or simply haven't caught up with a valuation that has already moved.
See the live data behind this article on ORTEX.
Open ABT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
